Please login to the form below

Not currently logged in


This page shows the latest Donanemab news and features for those working in and with pharma, biotech and healthcare.

Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval

Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval

This meant many patients were able to stop treatment after six months, resulting in fewer than 100 patients receiving 12 months of donanemab. ... The company’s application was based on results from a phase 2 trial in which donanemab demonstrated

Latest news

More from news
Approximately 7 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    Recently published study results for aducanumab and donanemab, both antibodies against amyloid, showed effects that indicated some improvement in cognition and daily function in patients with early Alzheimer’s. ... In the aforementioned aducanumab and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
IPG Health Medical Communications

We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...